Business
Therma Bright Reports on Progress of Inretio's Novel Clot Removal Device for Stroke Treatment
Toronto, Ontario--(Newsfile Corp. - February 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: ...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright Reports on Progress of Inretio's Novel Clot Removal Device for Stroke TreatmentToronto, Ontario--(Newsfile Corp. - February 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (\"Therma\" or the \"Company\"), developer and partner in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. (\"Inretio\"), a leading Israeli medical device startup developing a novel clot removal device for use in treating ischemic stroke patients. Inretio recently announced promising results for its PREVA™ mechanical thrombectomy device for ischemic stroke treatment. The device has been undergoing a Good Laboratory Practice (GLP) animal study, at the Shamir Medical Center's Research Unit, which is world renowned for its innovation research in Israel. The study is progressing as planned, demonstrating the PREVA™ device's ability to remove 100% of a blood clot in 85% of the cases.The results of the GLP study are a positive sign for the device's future development and potential regulatory approval and commercialization. The study is expected to be completed during the second quarter of 2023, at which point Inretio plans to submit the data, as well as mechanical verification and validation (V&V) testing data, to the Israeli Ministry of Health for Clinical Trial clearance in humans, which will be a significant milestone towards commercialization.\"We are thrilled with the progress of our PREVA™ device and the positive results we've seen in the GLP study,\" said Raviv Vine, CEO of Inretio. \"Our team has worked tirelessly to develop a device that could make a meaningful difference in the treatment of ischemic stroke, and we believe that these results bring us one step closer to achieving that goal.\"Current mechanical solutions are based on stents that open inside the clot without aspiration, often resulting in fragmentation of the clot, which can lead to the creation of new blockages downstream and cause secondary damage to the brain tissue. Even a minor reduction and blood flow during the procedure can have a significant impact on the patient's future quality of life.The PREVA™ device is designed to mechanically remove blood clots in the brain, which is a critical factor in the treatment of ischemic stroke. I...